Cost-effectiveness plane showing 1000 replications from a distribution of cost and quality-adjusted life year (QALY) differences (angiotensin converting enzyme inhibitor vs microalbuminuria screening).

Cost effectiveness plane for studies with costs per DFD/QALY.

Thomas Grochtdreis (741198)
Christian Brettschneider (389547)
Annemarie Wegener (741199)
Birgit Watzke (741200)
Steffi Riedel-Heller (434691)
Martin Härter (374186)
Hans-Helmut König (63648)

May 2015

In capitals: studies with a societal perspective, in italics: studies with costs per DFD, in bold...

Cost-effectiveness plane for number of urinary tract infections prevented during 12 months (cranberry prophylaxis vs TMP-SMX prophylaxis).

Judith E. Bosmans (162999)
Mariëlle A. J. Beerepoot (298430)
Jan M. Prins (175858)
Gerben ter Riet (3639)
Suzanne E. Geerlings (264025)

April 2014

The black dot indicates the point estimate of the ICER (1.6 prevented UTIs less and €247 more cos...

Cost-effectiveness plane.

Barbara Barrett (489210)
Waquas Waheed (489211)
Simone Farrelly (489212)
Max Birchwood (489213)
Graham Dunn (489214)
Clare Flach (489215)
Claire Henderson (489216)
Morven Leese (489217)
Helen Lester (164644)
Max Marshall (489218)
Diana Rose (342126)
Kim Sutherby (489219)
George Szmukler (489220)
Graham Thornicroft (44441)
Sarah Byford (405086)

November 2013

A) Showing bootstrapped cost and effectiveness pairs for Whites, using societal costs. B) Showing...

Cost-effectiveness plane for the differences in QALY scores at 6 months (in Euros).

Janet L. MacNeil Vroomen (162993)
Marijke Boorsma (94852)
Judith E. Bosmans (162999)
Dinnus H. M. Frijters (163003)
Giel Nijpels (33705)
Hein P. J. van Hout (145857)

May 2012

Cost-effectiveness plane for the differences in QALY scores at 6 months (in Euros).</p

Incremental cost-effectiveness plane.

Jelena Stevanović (610519)
Marjolein Pompen (610520)
Hoa H. Le (610521)
Mark H. Rozenbaum (444489)
Robert G. Tieleman (610522)
Maarten J. Postma (239601)

August 2014

Incremental cost-effectiveness plane presents the incremental cost-effectiveness ratios of apixab...

Cost-effectiveness plane for the difference in quality of care sum score at 6 months (in Euros).

Janet L. MacNeil Vroomen (162993)
Marijke Boorsma (94852)
Judith E. Bosmans (162999)
Dinnus H. M. Frijters (163003)
Giel Nijpels (33705)
Hein P. J. van Hout (145857)

May 2012

Cost-effectiveness plane for the difference in quality of care sum score at 6 months (in Euros).<...

Incremental cost-effectiveness plane.

Soyon Lee (303769)
Rachel Mullin (303770)
Jon Blazawski (303771)
Craig I. Coleman (287485)

February 2013

Incremental cost-effectiveness plane showing Monte Carlo estimates of incremental costs and benef...

Cost-effectiveness plane presenting all non-dominated and selected dominated screening protocols and frequencies targeting injection drug users in ORT.

Lauren E. Cipriano (134538)
Gregory S. Zaric (134542)
Mark Holodniy (134544)
Eran Bendavid (134546)
Douglas K. Owens (117176)
Margaret L. Brandeau (134549)

September 2012

Cost-effectiveness plane presenting all non-dominated and selected dominated screening protocols ...

Univariate sensitivity analyses: effects of varying base-case estimates on the incremental cost-effectiveness ratio of treating all patients with ACE inhibitors vs screening for microalbuminuria (reference strategy).

Charles Christian Adarkwah (342183)
Afschin Gandjour (342184)
Maren Akkerman (342185)
Silvia M. Evers (342186)

February 2013

QALYs = quality-adjusted life years; ACE = angiotensin-converting enzyme; ESRD = end-stage ...

Cost-effectiveness plane for each QALY gained, cardiorespiratory fitness (ml/kg/min), and lean muscle mass.

Päivi Kolu (220879)
Jani Raitanen (220886)
Clas-Håkan Nygård (781806)
Eija Tomás (781807)
Riitta Luoto (49203)

August 2015

Cost-effectiveness plane for each QALY gained, cardiorespiratory fitness (ml/kg/min), and lean mu...

Cost-effectiveness plane – cost per Fallot patient over 55 years graphed against the QALY gained compared to natural progression –10,000 simulations.

Rachael Maree Hunter (393680)
Mark Isaac (393681)
Alessandra Frigiola (393682)
David Blundell (393683)
Kate Brown (393684)
Kate Bull (368242)

March 2013

Cost-effectiveness plane – cost per Fallot patient over 55 years graphed against the QALY gained ...

Cost-effectiveness plane of lifetime cost and effectiveness of four treatment strategies.

Waranya Rattanavipapong (736370)
Thunyarat Anothaisintawee (840641)
Yot Teerawattananon (180232)

February 2018

Cost-effectiveness plane of lifetime cost and effectiveness of four treatment strategies.</p

Cost-effectiveness plane comparing the effectiveness of status quo (no screening) and the four screening strategies (opportunistic examination, systematic examination, systematic photography, and opportunistic treatment).

Ra Ho (5917445)
Lina D. Song (5917448)
Jin A. Choi (559035)
Donghyun Jee (480337)

October 2018

Cost-effectiveness plane comparing the effectiveness of status quo (no screening) and the four scree...

Cost-effectiveness analysis.

Shan Liu (193759)
Lauren E. Cipriano (134538)
Mark Holodniy (134544)
Jeremy D. Goldhaber-Fiebert (117177)

March 2013

(A) The graph plots the incremental discounted QALYs (y-axis) and incremental discounted l...

Cost-effectiveness plane scatter plot for the (A) DURATION-6 clinical input and (B) Scott and colleagues’ meta-analysis clinical input analyses.

Bruce Wang (3257)
Joshua A. Roth (717765)
Hiep Nguyen (717766)
Eugene Felber (717767)
Wes Furnback (717768)
Louis P. Garrison (182511)

April 2015

The figure displays the incremental HbA1c (x axis) and incremental cost (y axis) outcomes of 5,00...

Cost effectiveness plane for studies with costs per DFD/QALY.

Thomas Grochtdreis (741198)
Christian Brettschneider (389547)
Annemarie Wegener (741199)
Birgit Watzke (741200)
Steffi Riedel-Heller (434691)
Martin Härter (374186)
Hans-Helmut König (63648)

May 2015

In capitals: studies with a societal perspective, in italics: studies with costs per DFD, in bold...

Cost-effectiveness plane for number of urinary tract infections prevented during 12 months (cranberry prophylaxis vs TMP-SMX prophylaxis).

Judith E. Bosmans (162999)
Mariëlle A. J. Beerepoot (298430)
Jan M. Prins (175858)
Gerben ter Riet (3639)
Suzanne E. Geerlings (264025)

April 2014

The black dot indicates the point estimate of the ICER (1.6 prevented UTIs less and €247 more cos...

Cost-effectiveness plane.

Barbara Barrett (489210)
Waquas Waheed (489211)
Simone Farrelly (489212)
Max Birchwood (489213)
Graham Dunn (489214)
Clare Flach (489215)
Claire Henderson (489216)
Morven Leese (489217)
Helen Lester (164644)
Max Marshall (489218)
Diana Rose (342126)
Kim Sutherby (489219)
George Szmukler (489220)
Graham Thornicroft (44441)
Sarah Byford (405086)

November 2013

A) Showing bootstrapped cost and effectiveness pairs for Whites, using societal costs. B) Showing...

Cost-effectiveness plane for the differences in QALY scores at 6 months (in Euros).

Janet L. MacNeil Vroomen (162993)
Marijke Boorsma (94852)
Judith E. Bosmans (162999)
Dinnus H. M. Frijters (163003)
Giel Nijpels (33705)
Hein P. J. van Hout (145857)

May 2012

Cost-effectiveness plane for the differences in QALY scores at 6 months (in Euros).</p

Incremental cost-effectiveness plane.

Jelena Stevanović (610519)
Marjolein Pompen (610520)
Hoa H. Le (610521)
Mark H. Rozenbaum (444489)
Robert G. Tieleman (610522)
Maarten J. Postma (239601)

August 2014

Incremental cost-effectiveness plane presents the incremental cost-effectiveness ratios of apixab...

Cost-effectiveness plane for the difference in quality of care sum score at 6 months (in Euros).

Janet L. MacNeil Vroomen (162993)
Marijke Boorsma (94852)
Judith E. Bosmans (162999)
Dinnus H. M. Frijters (163003)
Giel Nijpels (33705)
Hein P. J. van Hout (145857)

May 2012

Cost-effectiveness plane for the difference in quality of care sum score at 6 months (in Euros).<...

Incremental cost-effectiveness plane.

Soyon Lee (303769)
Rachel Mullin (303770)
Jon Blazawski (303771)
Craig I. Coleman (287485)

February 2013

Incremental cost-effectiveness plane showing Monte Carlo estimates of incremental costs and benef...

Cost-effectiveness plane presenting all non-dominated and selected dominated screening protocols and frequencies targeting injection drug users in ORT.

Lauren E. Cipriano (134538)
Gregory S. Zaric (134542)
Mark Holodniy (134544)
Eran Bendavid (134546)
Douglas K. Owens (117176)
Margaret L. Brandeau (134549)

September 2012

Cost-effectiveness plane presenting all non-dominated and selected dominated screening protocols ...

Univariate sensitivity analyses: effects of varying base-case estimates on the incremental cost-effectiveness ratio of treating all patients with ACE inhibitors vs screening for microalbuminuria (reference strategy).

Charles Christian Adarkwah (342183)
Afschin Gandjour (342184)
Maren Akkerman (342185)
Silvia M. Evers (342186)

February 2013

QALYs = quality-adjusted life years; ACE = angiotensin-converting enzyme; ESRD = end-stage ...

Cost-effectiveness plane for each QALY gained, cardiorespiratory fitness (ml/kg/min), and lean muscle mass.

Päivi Kolu (220879)
Jani Raitanen (220886)
Clas-Håkan Nygård (781806)
Eija Tomás (781807)
Riitta Luoto (49203)

August 2015

Cost-effectiveness plane for each QALY gained, cardiorespiratory fitness (ml/kg/min), and lean mu...

Cost-effectiveness plane – cost per Fallot patient over 55 years graphed against the QALY gained compared to natural progression –10,000 simulations.

Rachael Maree Hunter (393680)
Mark Isaac (393681)
Alessandra Frigiola (393682)
David Blundell (393683)
Kate Brown (393684)
Kate Bull (368242)

March 2013

Cost-effectiveness plane – cost per Fallot patient over 55 years graphed against the QALY gained ...

Cost-effectiveness plane of lifetime cost and effectiveness of four treatment strategies.

Waranya Rattanavipapong (736370)
Thunyarat Anothaisintawee (840641)
Yot Teerawattananon (180232)

February 2018

Cost-effectiveness plane of lifetime cost and effectiveness of four treatment strategies.</p

Cost-effectiveness plane comparing the effectiveness of status quo (no screening) and the four screening strategies (opportunistic examination, systematic examination, systematic photography, and opportunistic treatment).

Ra Ho (5917445)
Lina D. Song (5917448)
Jin A. Choi (559035)
Donghyun Jee (480337)

October 2018

Cost-effectiveness plane comparing the effectiveness of status quo (no screening) and the four scree...

Cost-effectiveness analysis.

Shan Liu (193759)
Lauren E. Cipriano (134538)
Mark Holodniy (134544)
Jeremy D. Goldhaber-Fiebert (117177)

March 2013

(A) The graph plots the incremental discounted QALYs (y-axis) and incremental discounted l...

Cost-effectiveness plane scatter plot for the (A) DURATION-6 clinical input and (B) Scott and colleagues’ meta-analysis clinical input analyses.

Bruce Wang (3257)
Joshua A. Roth (717765)
Hiep Nguyen (717766)
Eugene Felber (717767)
Wes Furnback (717768)
Louis P. Garrison (182511)

April 2015

The figure displays the incremental HbA1c (x axis) and incremental cost (y axis) outcomes of 5,00...

Cost effectiveness plane for studies with costs per DFD/QALY.

Thomas Grochtdreis (741198)
Christian Brettschneider (389547)
Annemarie Wegener (741199)
Birgit Watzke (741200)
Steffi Riedel-Heller (434691)
Martin Härter (374186)
Hans-Helmut König (63648)

May 2015

In capitals: studies with a societal perspective, in italics: studies with costs per DFD, in bold...

Cost-effectiveness plane for number of urinary tract infections prevented during 12 months (cranberry prophylaxis vs TMP-SMX prophylaxis).

Judith E. Bosmans (162999)
Mariëlle A. J. Beerepoot (298430)
Jan M. Prins (175858)
Gerben ter Riet (3639)
Suzanne E. Geerlings (264025)

April 2014

The black dot indicates the point estimate of the ICER (1.6 prevented UTIs less and €247 more cos...

Cost-effectiveness plane.

Barbara Barrett (489210)
Waquas Waheed (489211)
Simone Farrelly (489212)
Max Birchwood (489213)
Graham Dunn (489214)
Clare Flach (489215)
Claire Henderson (489216)
Morven Leese (489217)
Helen Lester (164644)
Max Marshall (489218)
Diana Rose (342126)
Kim Sutherby (489219)
George Szmukler (489220)
Graham Thornicroft (44441)
Sarah Byford (405086)

November 2013

A) Showing bootstrapped cost and effectiveness pairs for Whites, using societal costs. B) Showing...

Cost-effectiveness plane showing 1000 replications from a distribution of cost and quality-adjusted life year (QALY) differences (angiotensin converting enzyme inhibitor vs microalbuminuria screening).

Abstract

Extracted data

Cost-effectiveness plane showing 1000 replications from a distribution of cost and quality-adjusted life year (QALY) differences (angiotensin converting enzyme inhibitor vs microalbuminuria screening).

Abstract

Extracted data

Related items

Related items